Pharma industry R&D investment funding for neglected diseases continues to be a good news story

The International Federations of Pharmaceutical Manufacturers Associations (IFPMA), welcomes the 10th annual G-FINDER report results that show industry contributed $497 million to global R&D efforts, accounting for 16% of total global funding.

The report notes that industry funding has reached new record highs for the last three years. Since 2008, reported industry investment has increased by nearly 50%. This firmly consolidates industry’s position as the third largest funder of R&D for neglected diseases after the US National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation. G-FINDER notes that “the sustained growth in industry investment in neglected disease R&D continues to be a good story.”

A large proportion ($391 million, 79%) of industry investment can be attributed to major research-based biopharmaceutical companies (listed in the G-FINDER report as multinational companies “MNCs”). Increasingly, the research-based biopharmaceutical industry engages in a variety of multi-sectoral research models to ensure that new generations of improved treatments and interventions are discovered, despite low commercial incentives in the area of NTDs.